Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging

Soonmee Cha; Janine Lupo; M.-H. Chen; Kathleen R. Lamborn; Michael W. McDermott

doi:10.3174/ajnr.a0484

Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging

Soonmee Cha, Janine Lupo, M.-H. Chen, Kathleen R. Lamborn, Michael W. McDermott, Mitchel S. Berger, Sarah J. Nelson, William P. Dillon

American Society of Neuroradiology (2007) • Volume 28, Issue 6, Pages 1078-1084

PDF Available

Abstract

The findings of our study show that the peak height and the percentage of signal intensity recovery derived from the Delta R2* curve of DSC perfusion MR imaging can differentiate GBM and MET.

Quick Actions

Read Full Paper

Publication Info

DOI

10.3174/ajnr.a0484

Language

English

Topic

MRI in cancer diagnosis

Keywords

Medicine, Nuclear medicine, Glioblastoma, Intensity (physics), Magnetic resonance imaging, Perfusion, Lesion, Gadolinium, Contrast (vision), Pathology, Radiology, Chemistry, Cancer research

Published

June 1, 2007

Citations

286 citations

FWCI

8.36

External Resources

DOI Link OpenAlex

Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

Shaping the Future of Healthcare: Ethical Clinical Challenges and Pathways to Trustworthy AI

Redox regulation: mechanisms, biology and therapeutic targets in diseases

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Suggested Papers

Suggested Papers

Shaping the Future of Healthcare: Ethical Clinical Challenges and Pathways to Trustworthy AI

Redox regulation: mechanisms, biology and therapeutic targets in diseases

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001